Evonik Venture Capital
VC Fund
Hanau, Germany
Evonik Venture Capital is a VC fund in Hanau focused on Biotechnology and Manufacturing. Evonik Venture Capital is the corporate venture arm of Evonik Industries AG, one of the providers of specialty chemicals. Evonik Venture Capital invests in young companies with innovative technology and high growth potential with solutions to problems within the areas of focus of resource efficiency, specialty additives, health & care,nutrition.
- Total investments:
- 43
- Last investment:
- Lead investor:
- 40%
- Fund size:
- $169M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Evonik Venture Capital invests in
Stages Evonik Venture Capital invests in
Countries Evonik Venture Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $3M–$15M
- Series B
- $18M–$38M
- Venture - Series Unknown
- $14M–$39M
Investment Focus
Industry
- Biotechnology 9 (21%)
- Manufacturing 8 (19%)
- Health Care 7 (16%)
- Software 4 (9%)
- 3D Printing 4 (9%)
Stage
- Venture - Series Unknown 10 (23%)
- Series A 7 (16%)
- Series B 4 (9%)
- Series C 4 (9%)
- Seed 3 (7%)
Country
- United States 8 (19%)
- China 4 (9%)
- The Netherlands 3 (7%)
- Israel 2 (5%)
- Finland 2 (5%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Bernhard Mohr
Managing Director
|
Managing Director | Total investments: 18 | Find email | |
Eric Breese
Investment Director
|
Investment Director | Total investments: 0 | Find email | |
Lars Bönisch
Venture Capitalist
|
Venture Capitalist | Total investments: 2 | Find email | |
|
Thomas Grosse-Puppendahl
Vice President, Operations
|
Vice President, Operations | Total investments: 3 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Abolis is a French company delivering high-impact innovations in biotechnologies that supports industries in their transition to build a better future in collaboration with Nature. We provide tailor-made industrial solutions based on micro-organisms. Founded in 2014, Abolis is made up of a team of over 54 people, sharing a scientific and humanistambition. Determined to become a key player in the transformation of manufacturing, we combine our expertise in biology, fermentation, IT, robotics, analytics and industrial property to reinvent the future of numerous industries - from food to healthcare, cosmetics and chemicals. We help industries make the ecological transition by rethinking their production models We rely on biotechnologies and the untapped potential of micro-organisms to develop new bioproduction solutions that are economically and ecologically sustainable alternatives to petrochemical products and chemical ingredients. We take up the industry's current challenges by: · Using renewable raw materials · Relocate essential production and secure supply chains · Designing biocompatible products less toxic for the environment · Reducing greenhouse gas emissions Abolis is providing tailor-made industrial solutions, based on microorganisms We are… independent in thought and action rigorous in our approach and the way we work creative because we never stop innovating, while remaining pragmatic ambitious because we are passionate and determined to make a difference | $38.8M / Venture - Series Unknown / Sep 12, 2024 | ||
| Strohm is a private supply chain company, focused on the offshore wind-to-hydrogen sector. | $31.8M / Venture - Series Unknown / Jun 19, 2024 | ||
| Velox develops and manufactures industrial-grade direct-to shape digital decoration solutions for the rigid container industry. Their proprietary DTS-Inkjet technology, based on uniquely formulated inks and dedicated deposition architecture, introduces an entirely new approach to digital printing that is poised to disrupt the packaging decorationmarket.Their debut product is the Velox IDS 250 – the first industrial-grade digital decorator for mass production of cylindrical containers available on the market. It delivers superior decoration quality and capabilities that outstrip analog printing solutions, while allowing a more efficient and flexible production process and a low total cost of ownership (TCO).Velox is powered by an expert team with uniquely extensive and wide-ranging experience in digital printing. It is led by veteran executives with proven success in driving company growth. | $38M / Series B / Apr 02, 2024 | ||
| Jiangsu Jland Biotech is dedicated to the development and production of Biollagen™ collagen and is determined to be the biggest non-animal-sourced collagen supplier worldwide. | Series B / Sep 25, 2023 | ||
| HPNow is pioneering the market introduction of powerful, autonomous, safe and eco-friendly water and air treatment solutions, based on their technological breakthroughs in on-site generation of hydrogen peroxide. HPNow’s technology enables on-demand, highly-efficient production of hydrogen peroxide using only water, electricity and air.Withtheir compact and autonomous on-site HPGenTM hydrogen-peroxide generators, they are set to displace presently used and increasingly regulated chlorine and other toxic-chemical disinfectants across multiple water and air treatment sectors. In doing so they will provide our users with cost savings, reduced logistical burdens, and increased yields, while enhancing water, air and food safety and reducing the environmental impact of today’s toxic disinfectant agents. | $15M / Series A / Sep 19, 2023 | ||
| SuperC is an enterprise that specializes in the research and production of innovative nanomaterials. The company was founded in 2012 and is headquartered in Dongguan City, Guangdong, China. | Venture - Series Unknown / Feb 20, 2023 | ||
| Strohm is a private supply chain company, focused on the offshore wind-to-hydrogen sector. | $16M / Venture - Series Unknown / Dec 15, 2022 | ||
| Allay Therapeutics offers analgesic products for post-surgical pain management and recuperation. The company was founded in 2017 and is headquartered in Menlo Park, California, United States. | Series C / Dec 13, 2022 | ||
| Strohm is a private supply chain company, focused on the offshore wind-to-hydrogen sector. | $14.4M / Venture - Series Unknown / Aug 12, 2022 | ||
| Medical device company developing a closure device for vascular access procedures. | $23M / Series D / May 17, 2022 | ||
| See all 43 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Evonik Venture Capital invest in?
Evonik Venture Capital invests primarily in Biotechnology, Manufacturing and Health Care startups, most often at Venture - Series Unknown and Series A stage. Most of the 43 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Evonik Venture Capital's check size?
Evonik Venture Capital typically joins rounds of $3M–$15M at Series A, $18M–$38M at Series B and $14M–$39M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Evonik Venture Capital participates in.
How do I contact Evonik Venture Capital?
Public channels for Evonik Venture Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Evonik Venture Capital?
The team at Evonik Venture Capital includes Bernhard Mohr (Managing Director), Eric Breese (Investment Director) and Lars Bönisch (Venture Capitalist). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
